PGEN vs. ATAI, SBTX, NKTX, AVIR, NATR, VTYX, VRCA, KMDA, ORGO, and CRMD
Should you be buying Precigen stock or one of its competitors? The main competitors of Precigen include Atai Life Sciences (ATAI), Silverback Therapeutics (SBTX), Nkarta (NKTX), Atea Pharmaceuticals (AVIR), Nature's Sunshine Products (NATR), Ventyx Biosciences (VTYX), Verrica Pharmaceuticals (VRCA), Kamada (KMDA), Organogenesis (ORGO), and CorMedix (CRMD). These companies are all part of the "pharmaceutical preparations" industry.
Precigen (NASDAQ:PGEN) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, community ranking, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.
Precigen received 100 more outperform votes than Atai Life Sciences when rated by MarketBeat users. Likewise, 67.03% of users gave Precigen an outperform vote while only 65.92% of users gave Atai Life Sciences an outperform vote.
33.5% of Precigen shares are owned by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are owned by institutional investors. 41.7% of Precigen shares are owned by company insiders. Comparatively, 30.0% of Atai Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Precigen has a net margin of -1,540.63% compared to Atai Life Sciences' net margin of -12,810.51%. Atai Life Sciences' return on equity of -45.08% beat Precigen's return on equity.
Precigen has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.
Atai Life Sciences has lower revenue, but higher earnings than Precigen. Atai Life Sciences is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Precigen had 1 more articles in the media than Atai Life Sciences. MarketBeat recorded 3 mentions for Precigen and 2 mentions for Atai Life Sciences. Atai Life Sciences' average media sentiment score of 1.89 beat Precigen's score of 0.63 indicating that Atai Life Sciences is being referred to more favorably in the news media.
Precigen presently has a consensus price target of $10.00, indicating a potential upside of 687.40%. Atai Life Sciences has a consensus price target of $10.50, indicating a potential upside of 455.56%. Given Precigen's higher possible upside, analysts plainly believe Precigen is more favorable than Atai Life Sciences.
Summary
Precigen beats Atai Life Sciences on 10 of the 18 factors compared between the two stocks.
Get Precigen News Delivered to You Automatically
Sign up to receive the latest news and ratings for PGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Precigen Competitors List
Related Companies and Tools
